Oncology Business Review (OBR) is a primary information resource dedicated exclusively to the business of oncology. About Us»
(Bloomberg Businessweek) September 2, 2010 - People with osteoporosis who take drugs such as Boniva (ibandronate), Fosamax (alendronate) or Actonel (risedronate) to strengthen their bones may be at an increased risk of esophageal cancer, British researchers report.
read article »
(Reuters) September 3, 2010 - Celldex Therapeutics Inc said its partner Pfizer ended the deal to co-develop Celldex's cancer vaccine, its lead product, as the program was no longer a strategic priority for the drug giant.
read article »
 |
Our free daily oncology focused e-news service. Subscribe» | Search Archives» | |
Oncology Business Review is our industry trade journal with carefully developed, exclusive oncology industry content. SUBSCRIBE Today!
Our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register for OBR green today. View OBR green.
The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™
| Symbol | Price | Δ | % Δ |
Upcoming Market Moving Events.
View OBR Radar»
Date: September 17, 2010
Company: Roche AG / Genentech
Product: Avastin® (bevacizumab)
Date: September 30, 2010
Company: Eisai Co.
Product: eribulin mesylate ("eribulin," also known as E7389)
Date: Q3 or Q4 '10
Company: Celgene Corp.
Product: N/A
